Jupiter Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$448K Hold
8,500
0.18% 69
2025
Q4
$416K Hold
8,500
0.19% 62
2025
Q3
$551K Buy
8,500
+1,000
+13% +$57.4K 0.26% 60
2025
Q2
$430K Hold
7,500
0.22% 63
2025
Q1
$290K Hold
7,500
0.18% 59
2024
Q4
$295K Hold
7,500
0.15% 76
2024
Q3
$352K Hold
7,500
0.18% 71
2024
Q2
$430K Hold
7,500
0.23% 66
2024
Q1
$400K Hold
7,500
0.21% 66
2023
Q4
$470K Hold
7,500
0.28% 64
2023
Q3
$399K Hold
7,500
0.26% 61
2023
Q2
$421K Hold
7,500
0.36% 50
2023
Q1
$339K Hold
7,500
0.31% 47
2022
Q4
$304K Hold
7,500
0.29% 45
2022
Q3
$490K Hold
7,500
0.49% 41
2022
Q2
$455K Hold
7,500
0.41% 44
2022
Q1
$470K Hold
7,500
0.29% 61
2021
Q4
$568K Sell
7,500
-4,000
-35% -$349K 0.29% 57
2021
Q3
$1.01M Sell
11,500
-1,000
-8% -$126K 0.47% 49
2021
Q2
$1.71M Hold
12,500
0.82% 35
2021
Q1
$1.65M Sell
12,500
-500
-4% -$75.5K 0.83% 33
2020
Q4
$1.99M Hold
13,000
1.22% 26
2020
Q3
$1.09M Sell
13,000
-4,551
-26% -$404K 0.77% 33
2020
Q2
$1.67M Hold
17,551
0.84% 32
2020
Q1
$851K Buy
17,551
+35
+0.2% +$1.81K 0.5% 35
2019
Q4
$1.04M Sell
17,516
-26
-0.1% -$1.42K 0.51% 36
2019
Q3
$719K Sell
17,542
-30
-0.2% -$1.43K 0.38% 41
2019
Q2
$865K Buy
17,572
+151
+0.9% +$6.04K 0.43% 39
2019
Q1
$632K Buy
+17,421
New +$602K 0.3% 44

Other funds holding CRSP

Jupiter Wealth Management's CRSP Position: Q1 2026 in Review

Jupiter Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 8,500 shares worth $448K. The position accounts for 0.18% of the portfolio, ranked #69.

Jupiter Wealth Management first reported a position in CRSP in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.99M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Jupiter Wealth Management held 8,500 shares of CRISPR Therapeutics worth $448K as of Q1 2026.
  • Jupiter Wealth Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up 0.18% of Jupiter Wealth Management's portfolio in Q1 2026, its #69 holding.
  • Jupiter Wealth Management first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Jupiter Wealth Management's CRISPR Therapeutics position peaked at $1.99M in Q4 2020.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Jupiter Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.